Statistical, Clinical, Methodological Evaluation of Local Recurrence Following Transanal Total Mesorectal Excision for Rectal Cancer: A Systematic Review
- PMID: 33938532
- DOI: 10.1097/DCR.0000000000002110
Statistical, Clinical, Methodological Evaluation of Local Recurrence Following Transanal Total Mesorectal Excision for Rectal Cancer: A Systematic Review
Abstract
Background: A recent Norwegian moratorium challenged the status quo of transanal total mesorectal excision for rectal cancer by reporting increased early multifocal local recurrences.
Objective: The aim of this systematic review and meta-analysis was to evaluate the local recurrence rates following transanal total mesorectal excision as well as to assess statistical, clinical, and methodological bias in reports published to date.
Data sources: The PubMed and MEDLINE (via Ovid) databases were systematically searched.
Study selection: Descriptive or comparative studies reporting rates of local recurrence at a median follow-up of 6 months (or more) after transanal total mesorectal excision were included.
Interventions: Patients underwent transanal total mesorectal excision.
Main outcome measures: Local recurrence was any recurrence located in the pelvic surgery site. The untransformed proportion method of 1-arm meta-analysis was utilized. Untransformed percent proportion with 95% confidence interval was reported. Ad hoc meta-regression with the Omnibus test was utilized to assess risk factors for local recurrence. Among-study heterogeneity was evaluated: statistically by I2 and τ2, clinically by summary tables, and methodologically by a 33-item questionnaire.
Results: Twenty-nine studies totaling 2906 patients were included. The pooled rate of local recurrence was 3.4% (2.7%-4.0%) at an average of 20.1 months with low statistical heterogeneity (I2 = 0%). Meta-regression yielded no correlation between complete total mesorectal excision quality (p = 0.855), circumferential resection margin (p = 0.268), distal margin (p = 0.886), and local recurrence rates. Clinical heterogeneity was substantial. Methodological heterogeneity was linked to the excitement of novelty, loss aversion, reactivity to criticism, indication for transanal total mesorectal excision, nonprobability sampling, circular reasoning, misclassification, inadequate follow-up, reporting bias, conflict of interest, and self-licensing.
Limitations: The studies included had an observational design and limited sample and follow-up.
Conclusion: This systematic review found a pooled rate of local recurrence of 3.4% at 20 months. However, given the substantial clinical and methodological heterogeneity across the studies, the evidence for or against transanal total mesorectal excision is inconclusive at this time.
Copyright © The ASCRS 2021.
Conflict of interest statement
Twenty-nine studies totaling 2906 patients were included. The pooled rate of local recurrence was 3.4% (2.7%–4.0%) at an average of 20.1 months with low statistical heterogeneity (I2 = 0%). Meta-regression yielded no correlation between complete total mesorectal excision quality (p = 0.855), circumferential resection margin (p = 0.268), distal margin (p = 0.886), and local recurrence rates. Clinical heterogeneity was substantial. Methodological heterogeneity was linked to the excitement of novelty, loss aversion, reactivity to criticism, indication for transanal total mesorectal excision, nonprobability sampling, circular reasoning, misclassification, inadequate follow-up, reporting bias, conflict of interest, and self-licensing.
Comment in
-
Research Perspective on Statistical, Clinical, Methodological Evaluation of Local Recurrence Following Transanal Total Mesorectal Excision for Rectal Cancer: A Systematic Review.Dis Colon Rectum. 2021 Jul 1;64(7):915. doi: 10.1097/DCR.0000000000002111. Dis Colon Rectum. 2021. PMID: 33902090 No abstract available.
Similar articles
-
Transanal Total Mesorectal Excision in Mid-Low Rectal Cancer: Evaluation of the Learning Curve and Comparison of Short-term Results With Standard Laparoscopic Total Mesorectal Excision.Dis Colon Rectum. 2021 Apr 1;64(4):380-388. doi: 10.1097/DCR.0000000000001816. Dis Colon Rectum. 2021. PMID: 33394779
-
Association of Transanal Total Mesorectal Excision With Local Recurrence of Rectal Cancer.JAMA Netw Open. 2021 Feb 1;4(2):e2036330. doi: 10.1001/jamanetworkopen.2020.36330. JAMA Netw Open. 2021. PMID: 33533932 Free PMC article.
-
Completion Total Mesorectal Excision After Transanal Local Excision of Early Rectal Cancer: A Systematic Review and Meta-analysis.Dis Colon Rectum. 2022 May 1;65(5):628-640. doi: 10.1097/DCR.0000000000002407. Dis Colon Rectum. 2022. PMID: 35143429
-
Oncologic safety and technical feasibility of completion transanal total mesorectal excision after local excision; a cohort study from the International TaTME Registry.Surg Endosc. 2025 Feb;39(2):970-977. doi: 10.1007/s00464-024-11390-w. Epub 2024 Dec 11. Surg Endosc. 2025. PMID: 39663245
-
Minimally invasive transanal surgery is safe after incomplete polypectomy of low risk T1 rectal cancer: a systematic review.Colorectal Dis. 2019 Oct;21(10):1112-1119. doi: 10.1111/codi.14659. Epub 2019 May 23. Colorectal Dis. 2019. PMID: 31074574
Cited by
-
Implication of Different Tumor Biomarkers in Drug Resistance and Invasiveness in Primary and Metastatic Colorectal Cancer Cell Lines.Biomedicines. 2022 May 6;10(5):1083. doi: 10.3390/biomedicines10051083. Biomedicines. 2022. PMID: 35625820 Free PMC article.
-
Clinical using of innovative biodegradable stent with extension sleeve in Ta_tme for low rectal cancer with high risk of anastomotic leakage.Sci Rep. 2025 Feb 25;15(1):6797. doi: 10.1038/s41598-024-73935-2. Sci Rep. 2025. PMID: 40000647 Free PMC article.
-
TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial.Front Oncol. 2023 Nov 20;13:1304767. doi: 10.3389/fonc.2023.1304767. eCollection 2023. Front Oncol. 2023. PMID: 38053659 Free PMC article.
-
Correlation of Presacral Tumour Recurrence with Tumour Metastasis and Long-Term Tumour Recurrence Risk in Patients with Rectal Cancer.Evid Based Complement Alternat Med. 2022 Sep 28;2022:6202457. doi: 10.1155/2022/6202457. eCollection 2022. Evid Based Complement Alternat Med. 2022. Retraction in: Evid Based Complement Alternat Med. 2023 Jul 12;2023:9876291. doi: 10.1155/2023/9876291. PMID: 36212978 Free PMC article. Retracted.
References
-
- Funahashi K, Koike J, Teramoto T, et al. Transanal rectal dissection: a procedure to assist achievement of laparoscopic total mesorectal excision for bulky tumor in the narrow pelvis. Am J Surg. 2009;197:e46–e50.
-
- Targarona EM, Balague C, Pernas JC, et al. Can we predict immediate outcome after laparoscopic rectal surgery? Multivariate analysis of clinical, anatomic, and pathologic features after 3-dimensional reconstruction of the pelvic anatomy. Ann Surg. 2008;247:642–649.
-
- Fernández-Hevia M, Delgado S, Castells A, et al. Transanal total mesorectal excision in rectal cancer: short-term outcomes in comparison with laparoscopic surgery. Ann Surg. 2015;261:221–227.
-
- Denost Q, Adam JP, Rullier A, Buscail E, Laurent C, Rullier E. Perineal transanal approach: a new standard for laparoscopic sphincter-saving resection in low rectal cancer, a randomized trial. Ann Surg. 2014;260:993–999.
-
- Velthuis S, Nieuwenhuis DH, Ruijter TE, Cuesta MA, Bonjer HJ, Sietses C. Transanal versus traditional laparoscopic total mesorectal excision for rectal carcinoma. Surg Endosc. 2014;28:3494–3499.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources